IGF::OT::IGF : Analytical Services Center for Medications Development Program. September 15, 2013 - September 14, 2018. N01DA-13-8920.PURPOSE: To obligate funds to fully fund performance under T

IGF::OT::IGF：药物开发计划分析服务中心。

• 批准号: 9430207
• 负责人: FANG XINPING
• 金额: $ 27.82万
• 依托单位: XENOBIOTIC LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-15 至 2018-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9430207
• 关键词: Biological; Biological Assay; Clinical Research; Contractor; Contracts; Data; Drug abuse; Enzymes; Evaluation; Funding; Hair; Investigational Drugs; Medical; Methods; National Institute of Drug Abuse; Outcome Measure; Peptides; Performance; Pharmaceutical Preparations; Pharmacotherapy; Plasma; Procedures; Program Development; Proteins; Publishing; Saliva; Services; Specimen; Tissues; Urine; analytical method; drug of abuse; molecular marker; novel therapeutics; preclinical study; small molecule; therapy development

The Contractor shall carry out qualitative and/or quantitative assays for a variety of compounds in biological specimens collected from preclinical and clinical studies using validated analytical methods. The biological specimens include, but are not limited to, plasma/serum, urine, saliva, hair and tissues. The analytes include, but are not limited to, new medications and/or their metabolites, abused drugs/metabolites, potential concomitant medications/compounds, and surrogate outcome measures and/molecular biomarkers (small molecules, peptides, proteins, enzymes, etc). The Contractor shall also develop and validate new assay methods for medications/compounds for which established assays do not exist.

承包商应使用经验证的分析方法，对从临床前和临床研究中采集的生物样本中的各种化合物进行定性和/或定量分析。生物样本包括但不限于血浆/血清、尿液、唾液、毛发和组织。分析物包括但不限于新药和/或其代谢物、滥用药物/代谢物、潜在伴随药物/化合物以及替代结局指标和/或分子生物标志物（小分子、肽、蛋白质、酶等）。承包商还应开发并验证尚未建立检测方法的药物/化合物的新检测方法。